Pulsenmore Announces Full Year 2025 Earnings Conference Call
Rhea-AI Summary
Pulsenmore (NASDAQ: PLSM) will release full year 2025 financial results on March 30, 2026 at 8:30 a.m. Eastern Time and will host a conference call and webcast to review results, business highlights, and recent progress.
Management presenting includes Jonathan Adereth (Chairman), Dr. Elazar Sonnenschein (CEO), Eran Hirsh (CFO), and Mira Altmark-Sofer (VP Marketing). The live webcast link and replay will be available on the company's Investor Relations website.
Positive
- None.
Negative
- None.
News Market Reaction – PLSM
In the Mar 25 session, PLSM declined 5.51%, reflecting a notable negative market reaction. Argus tracked a trough of -8.0% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.0x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 09 | Commercial agreement | Positive | +0.9% | New commercial services agreement post-FDA clearance in U.S. prenatal care. |
| Feb 02 | First U.S. engagement | Positive | +4.8% | First U.S. commercial engagement for home pregnancy ultrasound product. |
| Jan 26 | Strategic agreement | Positive | +3.9% | Strategic Clalit agreement to deploy Pulsenmore FC for at-home fertility monitoring. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent commercial and regulatory milestones have been followed by modest positive price reactions.
In the last few months, Pulsenmore reported several commercial and regulatory milestones. On Jan 26, 2026, it announced a strategic agreement with Clalit for Pulsenmore FC, potentially worth $4.5 million over five years, with a 3.89% next-day gain. On Feb 2, 2026, its first U.S. commercial engagement led to a 4.79% move. A further commercial services agreement after FDA clearance on Feb 9, 2026 saw a 0.87% increase. Today’s earnings call notice fits into this pattern of ongoing commercialization updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
OMER,
The Company will host a conference call and webcast to discuss its financial results, business highlights, and recent progress.
Conference Call & Webcast Details
Date: March 30, 2026
Time: 8:30 a.m. Eastern Time/ 3:30 p.m. Israel Time
Webcast: https://teams.microsoft.com/meet/3845461353556?p=fcIpXc4mErwEAqo3Ir
Replay: The meeting will be recorded, and the recording will be made available following the meeting on the Company's Investor Relations website at: https://pulsenmore.com/investor_relations/
Pulsenmore's executive leadership team, including Jonathan Adereth, Chairman of the Board of Directors, Dr. Elazar Sonnenschein, Founder and Chief Executive Officer, Eran Hirsh, Chief Financial Officer, and Mira Altmark-Sofer, Vice President of Marketing, will host the call to review the Company's financial results, key strategic initiatives, and recent operational progress.
About Pulsenmore
Pulsenmore Ltd. is dedicated to revolutionizing maternal health through the development of home-use ultrasound technology that connect mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care. For more information, visit www.pulsenmore.com
This press release contains forward-looking statements. In particular, statements using words such as "may," "seek," "will," "consider," "likely," "assume," "estimate," "expect," "anticipate," "intend," "believe," "contemplate," "do not believe," "aim," "goal," "due," "predict," "plan," "project," "continue," "potential," "positioned," "guidance," "objective," "outlook," "trends," "future," "could," "would," "should," "target," "on track" or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to Pulsenmore's continued commercial momentum, clinician adoption expansion, strengthening its presence in the U.S. market following its Nasdaq listing and FDA De Novo authorization and executing on its mission to broaden access to remote prenatal care through physician-directed, technology-enabled solutions. Forward-looking statements reflect Pulsenmore's current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company's lack of operating history; the Company's current and future capital requirements and the Company's belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company's ability to manufacture, market and sell its products and to generate revenues; the Company's ability to maintain its relationships with key partners and grow relationships with new partners; the Company's ability to maintain or protect the validity of its
Investor Contact:
Miri Segal-Scharia
MS-IR LLC
msegal@ms-ir.com
Logo - https://mma.prnewswire.com/media/2942134/Pulsenmore_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/pulsenmore-announces-full-year-2025-earnings-conference-call-302724789.html
SOURCE Pulsenmore Ltd.